LOS ANGELES--(BUSINESS WIRE)--Auriga Laboratories™, Inc. (OTCBB:ARGA), a specialty pharmaceutical company with products for the treatment of acute respiratory diseases, dermatological conditions, and xerostomia, announced today that it has launched the two newest members of the Zinx™ family of cough cold medications. The introduction of these two new kits broadens the range of symptoms relieved by the Zinx™ family. The additional treatment options allow physicians greater prescribing flexibility and the continued convenience of two products in one kit. The new kits compete in the decongestant/antihistamine segment, representing 15 million annual prescriptions and almost $1 billion in annual sales (source: Wolters Kluwer Health Source® PHAST July 2007).
